N/A N=60 Assesment of Post-stroke Elbow Flexor Spasticity in Different Forearm Positions
Post-stroke Elbow Spasticity
Primary: Dynamic Component of Spasticity (Spasticity Angle) — 70; 60; 57.5 degree — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=243 Dysport® Adult Upper Limb Spasticity
Nervous System Disorders
Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale
Phase 3 N=109 Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
Post-Stroke Spasticity · Cerebrovascular Accident
Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the High-dose Groups…
Phase 3 N=192 IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity
Upper Limb Spasticity
Primary: Responder in Disability Assessment Scale (DAS) at Week 4 - Per Protocol Set — 51; 44 participants
N/A N=4 Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity
Spasticity
Primary: Change From Baseline Contralesional Corticospinal Excitability — 67.88; -37.23 microVolts
Phase 3 N=258 Dysport® Adult Upper Limb Spasticity Extension Study
Nervous System Disorders
Primary: Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 102; 62; 47; 11 Participants
N/A N=19 Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device
Upper Limb Spasticity
Primary: Decrease in Pain and Symptoms Caused by Hypertonia in the Upper Arm as Measured by an Improvement of 1 Point or Greater on the Modified Ashworth Scale (MAS) at Day 7…
Phase 3 N=235 BOTOX® Treatment in Pediatric Upper Limb Spasticity
Pediatrics · Muscle Spasticity · Cerebral Palsy
Primary: Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of the Principal Muscle Group at Weeks 4 and 6 — -1.87; -1.92; -1.21 score on a scale…
N/A N=23 Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity
Upper Extremity Spasticity · Stroke · Acquired Brain Injury
Primary: Change From Baseline in Arm Function Based on Motor Activities Log (MAL-O) — 1.52; 1.79 units on a scale
N/A N=103 Patient Targeted Upper Extremity Rehabilitation After Stroke
Stroke
Primary: Fugl-Meyer Assessment of the Upper Extremity — 4.08; 2.45 score on a scale — p=0.912
N/A N=108 Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
Muscle Spasticity
Primary: Muscle Tone as Measured by the Modified Ashworth Scale (MAS) in the Elbow at Baseline — 2; 6; 18; 39 Participants
N/A N=122 Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke
Stroke, Acute · Stroke · Hemiparesis
Primary: Fugl-Meyer Motor Assessment (FMA) - Motor Impairment Measure — 27.5; 29.8; 26.8; 31.8 units on a scale — p=0.18
N/A N=18 Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Multiple Sclerosis · Pathologic Processes · Demyelinating Diseases
Primary: Stabilization of Scores Using the Test d'Evaluation de la Performance Des Membres Supérieurs Des Personnes Agées (TEMPA) -Translasted in English to Mean "Performance…
N/A N=13 Rehabilitation of the Upper Extremity With Enhanced Proprioceptive Feedback Following Incomplete Spinal Cord Injury
Spinal Cord Injury · Tetraplegia · Paresis
Primary: Grasp Release Test — 58.5; 72.0; 77.5 Objects moved — p=<0.025
Phase 2 N=26 The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke
Stroke · Cerebrovascular Accident (CVA) · Hemiparesis
Primary: Mean Percent Change From Baseline in Area Under the Curve for Objectively Measured Spastic Catch Response of the Wrist Flexors at Fast Speed — 13.678; -8.783; 15.927…
Phase 2 N=83 Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
Upper Limb Spasticity
Primary: Change From Baseline at Week 6 on the Modified Ashworth Scale (MAS) in the Suprahypertonic Muscle Group (SMG) Score — -0.9; -1.0; -1.5; -0.8 score on a scale — p=0.7645
N/A N=4 Treatment of Hand Dysfunction After Stroke
Stroke
Primary: Fugl-Meyer Upper Limb Coordination Scale (FMUE) — 27.75; 48.50 units on a scale — p=.0001
N/A N=67 Contralaterally Controlled FES of Arm & Hand for Subacute Stroke Rehabilitation
Stroke · Hemiparesis · Hemiplegia
Primary: Change in Box and Block Test (BBT) Score at 6 Months Post-Treatment — 13.5; 12.6; 9.6 blocks
Phase 4 N=274 BOTOX® Economic Spasticity Trial (BEST)
Muscle Spasticity
Primary: Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24 — 40.9; 33.3 Percentage of Patients
Phase 4 N=42 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
Stroke · Upper Limb Spasticity
Primary: Time Between the Initial Injection and the Appearance of Reinjection Criteria as Evaluated by the Modified Ashworth Scale (MAS) and Spasticity Symptoms — 156; 32 days…
N/A N=10 Hand Function for Tetraplegia
Spinal Cord Injury · Tetraplegia
Primary: Grasp Release Test - Test of Functional Ability to Pick up and Move Objects — 2; 5.5 Number of Completions
N/A N=96 Multimodal Treatment for Hemiplegic Shoulder Pain
Stroke · Shoulder Pain
Primary: Brief Pain Inventory (BPI)- Short Form (SF) Question 3 (BPI-SF3) - Mean Change From Baseline — 7.1; 7.4; 8.1; -2.8 units on a scale
N/A N=15 Transcutaneous Electrical Spinal Stimulation to Restore Upper Extremity Functions in Spinal Cord Injury
Spinal Cord Injury Cervical · Upper Extremity Dysfunction
Primary: Graded and Redefined Assessment of Strength, Sensibility and Prehension Test (GRASSP Test) — 4.5; 19.4 score change before and after — p=<0.000
N/A N=2 High Definition Neuromuscular Stimulation in Tetraplegia
Spinal Cord Injury at C4-C6 Level
Primary: Change in Voluntary Movement — 2; 0 Participants
Phase 3 N=220 BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
Pediatrics · Muscle Spasticity · Cerebral Palsy
Primary: Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE) — 58.7 percentage of participants
Phase 4 N=60 SISTERS: Spasticity In Stroke Study - Randomized Study
Severe Spasticity
Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140
Phase 3 N=317 Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
Post-stroke Spasticity of the Upper Limb
Primary: Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern — -0.9; -0.5 units on a scale — p=<0.001
Phase 2 N=12 Extension of the MIME Robotic System for Stroke Rehabilitation
Stroke · Impaired Upper Extremity Function
Primary: Fugl-Meyer Test of Motor Function — 1.9; .8; 1.3; .8 units on a scale
N/A N=231 Evaluation of a Spasticity Management Program for People With Multiple Sclerosis
Multiple Sclerosis
Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale
N/A N=57 Objective Assessment of Upper Extremity Functioning of Stroke Patients Before and After Rehabilitation
Stroke
Primary: Fugl-Meyer Assessment. — 38.32; NA; 47.6; NA units on a scale